Greenwich LifeSciences (GLSI)
Market Price (6/28/2026): $19.8 | Market Cap: $288.4 MilSector: Health Care | Industry: Biotechnology
Greenwich LifeSciences (GLSI)
Market Price (6/28/2026): $19.8Market Cap: $288.4 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -13% Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -22 Mil Stock price has recently run up significantly12M Rtn12 month market price return is 120% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% Key risksGLSI key risks include [1] its total dependence on the successful clinical trial outcome and regulatory approval of its single product candidate, Show more. |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -13% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -22 Mil |
| Stock price has recently run up significantly12M Rtn12 month market price return is 120% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -12% |
| Key risksGLSI key risks include [1] its total dependence on the successful clinical trial outcome and regulatory approval of its single product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/26/2026
Greenwich LifeSciences (GLSI) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Fiscal Q1 2026 Earnings Miss and Widened Net Loss. Greenwich LifeSciences (GLSI) reported a significant earnings miss for fiscal Q1 2026, which ended on March 31, 2026. The company posted an Earnings Per Share (EPS) of -$0.39, missing the consensus estimate of -$0.3366 by 15.86%. This negative surprise, coupled with no revenue generated as the company remains in a pre-commercialization phase, led to a widened net loss of $(5.66) million in fiscal Q1 2026, compared to a net loss of $(2.74) million in the prior-year quarter. The stock experienced a 2.7% decline following this announcement around June 2026.
2. Increased Research and Development (R&D) Expenses and Capital Raising. The primary driver for the widened net loss in fiscal Q1 2026 was a substantial increase in R&D costs, stemming from the ramping up of clinical activity for GLSI's lead candidate, GLSI-100, in its global Phase III FLAMINGO-01 clinical trial. To fund these increasing trial expenses and ongoing operations, Greenwich LifeSciences executed multiple "at-the-market" offerings in early 2026. While crucial for drug development, such capital raises can lead to share dilution and exert downward pressure on the stock price.
Show more
Greenwich LifeSciences (GLSI) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Fiscal Q1 2026 Earnings Miss and Widened Net Loss. Greenwich LifeSciences (GLSI) reported a significant earnings miss for fiscal Q1 2026, which ended on March 31, 2026. The company posted an Earnings Per Share (EPS) of -$0.39, missing the consensus estimate of -$0.3366 by 15.86%. This negative surprise, coupled with no revenue generated as the company remains in a pre-commercialization phase, led to a widened net loss of $(5.66) million in fiscal Q1 2026, compared to a net loss of $(2.74) million in the prior-year quarter. The stock experienced a 2.7% decline following this announcement around June 2026.
2. Increased Research and Development (R&D) Expenses and Capital Raising. The primary driver for the widened net loss in fiscal Q1 2026 was a substantial increase in R&D costs, stemming from the ramping up of clinical activity for GLSI's lead candidate, GLSI-100, in its global Phase III FLAMINGO-01 clinical trial. To fund these increasing trial expenses and ongoing operations, Greenwich LifeSciences executed multiple "at-the-market" offerings in early 2026. While crucial for drug development, such capital raises can lead to share dilution and exert downward pressure on the stock price.
Show more
Updated on 6/26/2026
Greenwich LifeSciences (GLSI) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Fiscal Q1 2026 Earnings Miss and Widened Net Loss. Greenwich LifeSciences (GLSI) reported a significant earnings miss for fiscal Q1 2026, which ended on March 31, 2026. The company posted an Earnings Per Share (EPS) of -$0.39, missing the consensus estimate of -$0.3366 by 15.86%. This negative surprise, coupled with no revenue generated as the company remains in a pre-commercialization phase, led to a widened net loss of $(5.66) million in fiscal Q1 2026, compared to a net loss of $(2.74) million in the prior-year quarter. The stock experienced a 2.7% decline following this announcement around June 2026.
2. Increased Research and Development (R&D) Expenses and Capital Raising. The primary driver for the widened net loss in fiscal Q1 2026 was a substantial increase in R&D costs, stemming from the ramping up of clinical activity for GLSI's lead candidate, GLSI-100, in its global Phase III FLAMINGO-01 clinical trial. To fund these increasing trial expenses and ongoing operations, Greenwich LifeSciences executed multiple "at-the-market" offerings in early 2026. While crucial for drug development, such capital raises can lead to share dilution and exert downward pressure on the stock price.
3. Nasdaq Notices for Late Regulatory Filings. Greenwich LifeSciences received notices from Nasdaq regarding the late filing of its Form 10-K for the fiscal year ending December 31, 2025, and a subsequent Form 10-Q. The company cited higher R&D costs as a reason for the delay in the 10-K filing. These notices can signal operational or financial reporting issues, potentially impacting investor confidence and contributing to a negative stock trend.
4. Mixed Market Reception to Preliminary Clinical Trial Data. Greenwich LifeSciences presented preliminary open-label immune response data from its Phase III FLAMINGO-01 trial at the ASCO Meeting 2026, held from May 28 to June 2, 2026. While the company highlighted an increase in injection site reaction rates and preliminary data suggesting an approximate 70-80% reduction in recurrence rate in the non-HLA-A*02 arm, the market's general reaction to clinical trial news for GLSI has averaged a decrease of 1.43%. The "preliminary" nature of these findings, with statements that data were "not yet complete or fully reviewed" and "final outcomes may differ," likely introduced a level of uncertainty that tempered positive investor sentiment.
Show less
Greenwich LifeSciences (GLSI) stock has lost about 30% since 2/28/2026 because of the following key factors:
1. Fiscal Q1 2026 Earnings Miss and Widened Net Loss. Greenwich LifeSciences (GLSI) reported a significant earnings miss for fiscal Q1 2026, which ended on March 31, 2026. The company posted an Earnings Per Share (EPS) of -$0.39, missing the consensus estimate of -$0.3366 by 15.86%. This negative surprise, coupled with no revenue generated as the company remains in a pre-commercialization phase, led to a widened net loss of $(5.66) million in fiscal Q1 2026, compared to a net loss of $(2.74) million in the prior-year quarter. The stock experienced a 2.7% decline following this announcement around June 2026.
2. Increased Research and Development (R&D) Expenses and Capital Raising. The primary driver for the widened net loss in fiscal Q1 2026 was a substantial increase in R&D costs, stemming from the ramping up of clinical activity for GLSI's lead candidate, GLSI-100, in its global Phase III FLAMINGO-01 clinical trial. To fund these increasing trial expenses and ongoing operations, Greenwich LifeSciences executed multiple "at-the-market" offerings in early 2026. While crucial for drug development, such capital raises can lead to share dilution and exert downward pressure on the stock price.
3. Nasdaq Notices for Late Regulatory Filings. Greenwich LifeSciences received notices from Nasdaq regarding the late filing of its Form 10-K for the fiscal year ending December 31, 2025, and a subsequent Form 10-Q. The company cited higher R&D costs as a reason for the delay in the 10-K filing. These notices can signal operational or financial reporting issues, potentially impacting investor confidence and contributing to a negative stock trend.
4. Mixed Market Reception to Preliminary Clinical Trial Data. Greenwich LifeSciences presented preliminary open-label immune response data from its Phase III FLAMINGO-01 trial at the ASCO Meeting 2026, held from May 28 to June 2, 2026. While the company highlighted an increase in injection site reaction rates and preliminary data suggesting an approximate 70-80% reduction in recurrence rate in the non-HLA-A*02 arm, the market's general reaction to clinical trial news for GLSI has averaged a decrease of 1.43%. The "preliminary" nature of these findings, with statements that data were "not yet complete or fully reviewed" and "final outcomes may differ," likely introduced a level of uncertainty that tempered positive investor sentiment.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -28.6% change in GLSI stock from 2/28/2026 to 6/27/2026 was primarily driven by a -6.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 27.72 | 19.80 | -28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 14 | 15 | -6.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/27/2026| Return | Correlation | |
|---|---|---|
| GLSI | -28.6% | |
| Market (SPY) | 6.6% | 44.3% |
| Sector (XLV) | 0.5% | 33.4% |
Fundamental Drivers
The 126.8% change in GLSI stock from 11/30/2025 to 6/27/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 11302025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.73 | 19.80 | 126.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 14 | 15 | -6.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| GLSI | 126.8% | |
| Market (SPY) | 7.3% | 39.6% |
| Sector (XLV) | 2.6% | 23.8% |
Fundamental Drivers
The 101.0% change in GLSI stock from 5/31/2025 to 6/27/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312025 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.85 | 19.80 | 101.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 13 | 15 | -9.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/27/2026| Return | Correlation | |
|---|---|---|
| GLSI | 101.0% | |
| Market (SPY) | 25.1% | 36.0% |
| Sector (XLV) | 23.0% | 20.5% |
Fundamental Drivers
The 81.8% change in GLSI stock from 5/31/2023 to 6/27/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 5312023 | 6272026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.89 | 19.80 | 81.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 13 | 15 | -11.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/27/2026| Return | Correlation | |
|---|---|---|
| GLSI | 81.8% | |
| Market (SPY) | 81.3% | 29.7% |
| Sector (XLV) | 31.9% | 21.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GLSI Return | -33% | -38% | -31% | 7% | 87% | -13% | -50% |
| Peers Return | 43% | -20% | 3% | 78% | -33% | -14% | 20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| GLSI Win Rate | 42% | 50% | 25% | 50% | 42% | 33% | |
| Peers Win Rate | 46% | 50% | 46% | 58% | 75% | 33% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| GLSI Max Drawdown | -59% | -71% | -63% | -46% | -43% | -45% | |
| Peers Max Drawdown | -41% | -46% | -34% | -26% | -59% | -39% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: VRTX, ATYR, AVLN, CNXU, COAG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
How Low Can It Go
| Event | GLSI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.9% | -18.8% |
| % Gain to Breakeven | 42.6% | 23.1% |
| Time to Breakeven | 259 days | 79 days |
| 2024 Yen Carry Trade Unwind | ||
| % Loss | -17.6% | -7.8% |
| % Gain to Breakeven | 21.4% | 8.5% |
| Time to Breakeven | 497 days | 18 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -13.7% | -9.5% |
| % Gain to Breakeven | 15.8% | 10.5% |
| Time to Breakeven | 11 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -49.1% | -6.7% |
| % Gain to Breakeven | 96.6% | 7.1% |
| Time to Breakeven | 249 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.7% | -24.5% |
| % Gain to Breakeven | 230.5% | 32.4% |
| Time to Breakeven | 1292 days | 427 days |
In The Past
Greenwich LifeSciences's stock fell -29.9% during the 2025 US Tariff Shock. Such a loss loss requires a 42.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | GLSI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -29.9% | -18.8% |
| % Gain to Breakeven | 42.6% | 23.1% |
| Time to Breakeven | 259 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -49.1% | -6.7% |
| % Gain to Breakeven | 96.6% | 7.1% |
| Time to Breakeven | 249 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.7% | -24.5% |
| % Gain to Breakeven | 230.5% | 32.4% |
| Time to Breakeven | 1292 days | 427 days |
In The Past
Greenwich LifeSciences's stock fell -29.9% during the 2025 US Tariff Shock. Such a loss loss requires a 42.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Greenwich LifeSciences (GLSI)
Greenwich LifeSciences (GLSI) is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies. The company's core mission is to address breast cancer and other cancers that express the HER2/neu protein, aiming to provide novel treatment options in the oncology field.
The company's lead product candidate is GP2, an immunotherapy designed to prevent the recurrence of breast cancer. GP2 has successfully completed a Phase IIb clinical trial, marking a significant milestone in its development. This immunotherapy is specifically intended for patients who have previously undergone surgery for breast cancer, with the goal of reducing the risk of the disease returning.
Therefore, Greenwich LifeSciences primarily serves the market of breast cancer patients who have completed initial surgical treatment and are seeking advanced therapies to prevent recurrence. Its target customers are within the oncology sector, specifically the post-surgical patient population requiring preventative immunological treatments for HER2/neu-expressing cancers.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Greenwich LifeSciences (GLSI):
- It's like a small, highly focused Genentech working on new immunotherapies for breast cancer.
- Imagine a startup division of a major pharmaceutical like Merck or Roche, solely dedicated to developing immunotherapies for breast cancer.
AI Analysis | Feedback
- GP2: An immunotherapy drug candidate in Phase IIb clinical trials for preventing breast cancer recurrence.
AI Analysis | Feedback
Greenwich LifeSciences, Inc. (GLSI) is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies. Its lead product candidate, GP2, has completed Phase IIb clinical trials. At this stage of development, the company is primarily engaged in research, development, and clinical trials, rather than commercial sales of a product.
Therefore, Greenwich LifeSciences (GLSI) does not currently have major customers in the traditional sense, as it is not yet selling a commercialized product to individuals or other companies. Its primary activities are focused on advancing its drug candidates through clinical trials and seeking regulatory approval, not on generating revenue from product sales.
AI Analysis | Feedback
Creative Peptides
AI Analysis | Feedback
Snehal S. Patel, Chief Executive Officer, Chief Financial Officer, and Director
Mr. Patel possesses over 30 years of experience in executive management, corporate development, operations, and investment banking within the healthcare industry. He has provided consulting, management, and advisory services for R&D and manufacturing design, scale-up, and operations at numerous public and private biotech companies, focusing on clinical and pre-clinical assets in areas such as stem cell therapy, multiple sclerosis t-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. Prior to his current role, he served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, where his work centered on healthcare and biotech financing and strategic transactions. He also worked in operations and business development at consulting firms and at Bayer Corporation, specifically in the biotechnology division on the commercialization of recombinant Factor VIII and in Corporate Development involving licensing and M&A transactions. Mr. Patel frequently acquires company stock, indicating his confidence in Greenwich LifeSciences' future prospects.
F. Joseph Daugherty, M.D., Chief Medical Officer and Director
Dr. Daugherty brings over 35 years of experience in managing and overseeing biotechnology and biomedical projects. He is currently the Managing Partner of Phenolics, LLC and PharmaPrint, LLC, which are nutraceutical companies, and serves on the boards of several startup companies and a charitable foundation. Dr. Daugherty previously held positions as President, Chief Executive Officer, Chief Medical Officer, and Chairman of the board of directors at Eleos, Inc., a private, clinical-stage biotech company focused on anti-sense technology in cancer.
Jaye Thompson, M.S., Ph.D., Vice President, Clinical and Regulatory Affairs
Dr. Thompson holds the crucial role of Vice President, Clinical and Regulatory Affairs for Greenwich LifeSciences.
David B. McWilliams, Chairman of the Board
Mr. McWilliams has more than 40 years of experience in establishing biopharmaceutical and healthcare companies. He currently serves as the Chairman of the board of directors of BioHouston, Inc., an organization dedicated to advocating for Houston's life sciences industry. Mr. McWilliams has acted as a consultant and advisor at various levels for multiple private start-up biotech companies, assisting in the development of pre-clinical and clinical assets for cancer and other therapeutic areas. He was formerly the Chief Executive Officer of Greenwich LifeSciences. His career also includes roles as President of Harleco Diagnostics Division (EM Industries), General Manager and Program Manager of Abbott Laboratories, and Management Consultant at McKinsey & Company. He also served as Chief Executive Officer and President of Kallestad Diagnostics (Erbamont).
Mr. Patel possesses over 30 years of experience in executive management, corporate development, operations, and investment banking within the healthcare industry. He has provided consulting, management, and advisory services for R&D and manufacturing design, scale-up, and operations at numerous public and private biotech companies, focusing on clinical and pre-clinical assets in areas such as stem cell therapy, multiple sclerosis t-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment. Prior to his current role, he served as an investment banker at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, where his work centered on healthcare and biotech financing and strategic transactions. He also worked in operations and business development at consulting firms and at Bayer Corporation, specifically in the biotechnology division on the commercialization of recombinant Factor VIII and in Corporate Development involving licensing and M&A transactions. Mr. Patel frequently acquires company stock, indicating his confidence in Greenwich LifeSciences' future prospects.
F. Joseph Daugherty, M.D., Chief Medical Officer and Director
Dr. Daugherty brings over 35 years of experience in managing and overseeing biotechnology and biomedical projects. He is currently the Managing Partner of Phenolics, LLC and PharmaPrint, LLC, which are nutraceutical companies, and serves on the boards of several startup companies and a charitable foundation. Dr. Daugherty previously held positions as President, Chief Executive Officer, Chief Medical Officer, and Chairman of the board of directors at Eleos, Inc., a private, clinical-stage biotech company focused on anti-sense technology in cancer.
Jaye Thompson, M.S., Ph.D., Vice President, Clinical and Regulatory Affairs
Dr. Thompson holds the crucial role of Vice President, Clinical and Regulatory Affairs for Greenwich LifeSciences.
David B. McWilliams, Chairman of the Board
Mr. McWilliams has more than 40 years of experience in establishing biopharmaceutical and healthcare companies. He currently serves as the Chairman of the board of directors of BioHouston, Inc., an organization dedicated to advocating for Houston's life sciences industry. Mr. McWilliams has acted as a consultant and advisor at various levels for multiple private start-up biotech companies, assisting in the development of pre-clinical and clinical assets for cancer and other therapeutic areas. He was formerly the Chief Executive Officer of Greenwich LifeSciences. His career also includes roles as President of Harleco Diagnostics Division (EM Industries), General Manager and Program Manager of Abbott Laboratories, and Management Consultant at McKinsey & Company. He also served as Chief Executive Officer and President of Kallestad Diagnostics (Erbamont).
AI Analysis | Feedback
The key risks to Greenwich LifeSciences (GLSI) are primarily associated with its stage of development as a clinical-stage biopharmaceutical company focused on a single lead product.
*
Clinical Trial and Regulatory Risk
Greenwich LifeSciences' success is heavily dependent on the successful completion of clinical trials and subsequent regulatory approval for its lead product candidate, GP2 (also referred to as GLSI-100), an immunotherapy for breast cancer. GP2 is currently in a Phase III clinical trial (FLAMINGO-01). Despite positive preliminary safety data from earlier phases and the ongoing Phase III trial, and the FDA's Fast Track designation, there is no guarantee of successful trial outcomes or market approval. Biopharmaceutical product development inherently carries a significant risk of failure at various stages of clinical trials, and regulatory requirements can be stringent and subject to change, potentially leading to delays or outright rejection. Manufacturing and pharmacy process concerns have also posed regulatory challenges in the past, though these have been addressed. *Financial Risk and Capital Constraints
As a clinical-stage company, Greenwich LifeSciences has a history of substantial losses and does not generate revenue from product sales, anticipating continued losses as it advances GP2 through development and towards commercialization. The company requires significant additional financing to fund its operations and complete the development and potential commercialization of its product candidate. Its existing cash reserves are expected to fund operations for a limited period, necessitating ongoing efforts to raise capital. The reliance on "at-the-market" share sales for funding can lead to shareholder dilution, and a failure to secure adequate additional funds could force the company to delay or reduce its development programs. *Concentration Risk
The company's business is highly concentrated on a single immunotherapy, GP2 (GLSI-100), as its primary product candidate. While Greenwich LifeSciences is exploring follow-on indications to expand the patient population and target other HER2/neu-expressing cancers, the entire pipeline strategy revolves around this single asset. This singular focus means that any setback, delay, or failure related to GP2 would have a severe and potentially catastrophic impact on the company's financial performance and future viability.AI Analysis | Feedback
null
AI Analysis | Feedback
```html
Greenwich LifeSciences' lead product candidate, GP2, an immunotherapy focused on preventing breast cancer recurrences in patients who have previously undergone surgery, targets HER2/neu-expressing cancers. The addressable markets for products and services related to breast cancer, particularly HER2-positive and HER2-low cancers, and cancer immunotherapies, are substantial.
- The global breast cancer therapeutics market was estimated at USD 31.5 billion in 2024 and is projected to reach USD 71.3 billion by 2034, growing at a Compound Annual Growth Rate (CAGR) of 8.5%. Another estimate places the global breast cancer market size at USD 26.23 billion in 2025, expected to grow to USD 38.54 billion by 2034 with a CAGR of 4.37%.
- The global HER2-positive breast cancer treatment market is estimated at USD 11.38 billion in 2026 and is projected to reach USD 13.79 billion by 2031, with a CAGR of 3.92%. North America accounted for 41.52% of this market's revenue in 2025.
- The global HER2 inhibitors market was valued at approximately USD 8.36 billion in 2025 and is expected to increase to approximately USD 13.69 billion by 2032, growing at a CAGR of 7.3%.
- The global cancer immunotherapy market was valued at USD 136.39 billion in 2025 and is projected to reach approximately USD 367.63 billion by 2035, growing at a CAGR of 10.42%. Within this, the breast cancer segment is anticipated to show significant growth.
- For HER2-low cancers, which GP2 also addresses (HER2 1-2+ patients), the market size across the 7 major markets (7MM) was approximately USD 3.2 billion in 2024. This market is projected to grow to USD 8.997 billion by 2034 in leading countries (US, EU4, UK, and Japan), at a CAGR of 11%. The United States market for HER2-low cancers was approximately USD 1.6 billion in 2024.
AI Analysis | Feedback
The future revenue growth for Greenwich LifeSciences (GLSI) over the next 2-3 years is primarily driven by the advancement and potential commercialization of its lead product candidate, GP2 (GLSI-100), an immunotherapy aimed at preventing breast cancer recurrences.
- Successful Completion and Positive Data from the Phase III FLAMINGO-01 Clinical Trial: The ongoing global Phase III FLAMINGO-01 clinical trial evaluating GLSI-100 is a critical driver. The company expects to report topline efficacy and safety data once a prespecified number of recurrence events occurs, with a projected timeframe of 12 to 18 months, depending on event rates. Preliminary data from the non-HLA-A*02 arm of the trial have shown an approximately 80% reduction in recurrence rate after the primary immunization series. Positive outcomes from this trial are essential for subsequent regulatory submissions and potential market entry.
- Regulatory Approvals for GP2 (GLSI-100): The company is actively progressing toward filing a Biological License Application (BLA) with the FDA in the US and pursuing regulatory filings with European Medicines Agency (EMA) in Europe. The FDA's approval of the first commercially manufactured lot of GP2 vials for use in the Phase III trial has significantly de-risked the future BLA filing process from a manufacturing perspective. If approved, GLSI-100 could be granted up to 12 years of market exclusivity under current law.
- Commercial Manufacturing and Supply Chain Readiness: Greenwich LifeSciences has made substantial progress in establishing its commercial manufacturing capabilities. The company manufactured the first three commercial lots of GP2 active ingredient in 2023, capable of producing approximately 200,000 doses, and the first commercial lot of finished GP2 vials in 2024. This readiness in manufacturing and supply chain is crucial for a timely and efficient market launch following regulatory approval.
- Market Penetration Addressing Unmet Medical Need: Upon potential approval, GP2 is positioned to address a significant unmet need in preventing breast cancer recurrences, particularly in patients who do not adequately respond to existing treatments like Herceptin or Kadcyla. There are approximately 700,000 new breast cancer patients and 9.5 million breast cancer survivors in the US and EU in 2025. Successful market penetration within this patient population would be a key driver of revenue growth.
AI Analysis | Feedback
Share Repurchases
- Greenwich LifeSciences suspended its share repurchase program in July 2022.
- Prior to suspension, the company repurchased approximately 520,000 shares of common stock for an aggregate of about $7.5 million.
Share Issuance
- Between January 1, 2024, and September 30, 2024, Greenwich LifeSciences raised approximately $1.75 million through an At-The-Market (ATM) agreement and nearly $2.5 million through a private placement offering.
- In the first three weeks of January 2026, the company raised approximately $7 million via its ATM financing vehicle.
- Cash burn in 2024 was offset in part through the sale of common stock via an ATM program and a private placement. The company also sold $1.2 million worth of shares in the ATM arrangement between January 1 and April 11, 2025.
Capital Expenditures
- Greenwich LifeSciences reported minimal to no significant capital expenditures on physical assets, with recent financial snapshots listing Capital Expenditures as $0.0.
- The primary focus of capital utilization is on research and development, particularly funding for its Phase III FLAMINGO-01 clinical trial.
- Research and development expenses increased to $2,292,040 for the three months ended September 30, 2024, up from $2,158,167 in the same quarter the previous year, mainly due to increased clinical expenses.
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 25.26 |
| Mkt Cap | 62.6 |
| Rev LTM | 0 |
| Op Inc LTM | -5 |
| FCF LTM | -4 |
| FCF 3Y Avg | 984 |
| CFO LTM | -4 |
| CFO 3Y Avg | 1,196 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.1% |
| Rev Chg 3Y Avg | 9.9% |
| Rev Chg Q | 7.8% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 595.7% |
| Op Inc Chg 3Y Avg | 161.4% |
| Op Mgn LTM | 38.2% |
| Op Mgn 3Y Avg | 24.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 34.7% |
| CFO/Rev 3Y Avg | 21.5% |
| FCF/Rev LTM | 30.4% |
| FCF/Rev 3Y Avg | 17.7% |
Price Behavior
Price Behavior
| Market Price | $19.80 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 09/25/2020 | |
| Distance from 52W High | -41.0% | |
| 50 Days | 200 Days | |
| DMA Price | $24.33 | $19.46 |
| DMA Trend | up | down |
| Distance from DMA | -18.6% | 1.7% |
| 3M | 1YR | |
| Volatility | 88.7% | 95.3% |
| Downside Capture | 246.25 | 284.23 |
| Upside Capture | 84.04 | 321.86 |
| Correlation (SPY) | 41.3% | 37.1% |
GLSI Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.44 | 2.90 | 3.53 | 4.19 | 2.99 | 1.50 |
| Up Beta | 3.50 | 2.96 | 3.58 | 3.23 | 2.52 | 1.21 |
| Down Beta | -0.51 | -1.13 | 2.95 | 4.57 | 2.72 | 1.24 |
| Up Capture | 65% | 216% | 365% | 1608% | 1223% | 876% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 12 | 21 | 30 | 67 | 119 | 357 |
| Down Capture | -188% | 575% | 356% | 250% | 191% | 112% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 8 | 20 | 33 | 57 | 128 | 388 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLSI | |
|---|---|---|---|---|
| GLSI | 116.5% | 95.1% | 1.24 | - |
| Sector ETF (XLV) | 21.4% | 15.4% | 1.06 | 20.2% |
| Equity (SPY) | 21.2% | 12.4% | 1.26 | 36.4% |
| Gold (GLD) | 21.8% | 27.7% | 0.70 | 4.1% |
| Commodities (DBC) | 21.8% | 18.6% | 0.92 | -11.9% |
| Real Estate (VNQ) | 16.1% | 13.6% | 0.85 | 14.8% |
| Bitcoin (BTCUSD) | -44.2% | 42.5% | -1.25 | 29.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLSI | |
|---|---|---|---|---|
| GLSI | -12.0% | 79.0% | 0.18 | - |
| Sector ETF (XLV) | 7.0% | 14.8% | 0.29 | 20.7% |
| Equity (SPY) | 13.4% | 17.1% | 0.61 | 28.1% |
| Gold (GLD) | 17.8% | 18.3% | 0.79 | 3.5% |
| Commodities (DBC) | 7.4% | 19.5% | 0.28 | -2.7% |
| Real Estate (VNQ) | 3.4% | 18.9% | 0.08 | 20.3% |
| Bitcoin (BTCUSD) | 10.9% | 54.0% | 0.39 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GLSI | |
|---|---|---|---|---|
| GLSI | 14.5% | 426.6% | 0.45 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 2.6% |
| Equity (SPY) | 15.2% | 18.0% | 0.72 | 2.7% |
| Gold (GLD) | 11.8% | 16.1% | 0.60 | -3.6% |
| Commodities (DBC) | 5.9% | 18.0% | 0.26 | -0.4% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 2.2% |
| Bitcoin (BTCUSD) | 54.7% | 66.4% | 0.95 | 3.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/3/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 06/04/2026 | 10-Q |
| 12/31/2025 | 06/01/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/20/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 10/19/2023 | 10-Q |
| 06/30/2023 | 08/21/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 06/04/2026 | 10-Q |
| 12/31/2025 | 06/01/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/20/2025 | 10-Q |
| 12/31/2024 | 04/15/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/14/2024 | 10-Q |
| 03/31/2024 | 05/20/2024 | 10-Q |
| 12/31/2023 | 04/15/2024 | 10-K |
| 09/30/2023 | 10/19/2023 | 10-Q |
| 06/30/2023 | 08/21/2023 | 10-Q |
| 03/31/2023 | 05/22/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/15/2022 | 10-Q |
| 03/31/2022 | 05/20/2022 | 10-Q |
| 12/31/2021 | 03/21/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/20/2021 | 10-Q |
| 12/31/2020 | 03/31/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 09/28/2020 | 424B4 |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Patel, Snehal | CEO and CFO | Direct | Buy | 1142026 | 27.54 | 2,900 | 79,866 | 154,287,397 | Form |
| 2 | Patel, Snehal | CEO and CFO | Direct | Buy | 1052026 | 21.36 | 4,300 | 91,848 | 119,603,227 | Form |
| 3 | Patel, Snehal | CEO and CFO | Direct | Buy | 1022026 | 21.73 | 2,900 | 63,017 | 121,581,566 | Form |
| 4 | Patel, Snehal | CEO and CFO | Direct | Buy | 12192025 | 12.62 | 4,100 | 51,742 | 70,573,589 | Form |
| 5 | Patel, Snehal | CEO and CFO | Direct | Buy | 11282025 | 8.37 | 4,600 | 38,502 | 46,772,414 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Patel, Snehal | CEO and CFO | Direct | Buy | 1142026 | 27.54 | 2,900 | 79,866 | 154,287,397 | Form |
| 2 | Patel, Snehal | CEO and CFO | Direct | Buy | 1052026 | 21.36 | 4,300 | 91,848 | 119,603,227 | Form |
| 3 | Patel, Snehal | CEO and CFO | Direct | Buy | 1022026 | 21.73 | 2,900 | 63,017 | 121,581,566 | Form |
| 4 | Patel, Snehal | CEO and CFO | Direct | Buy | 12192025 | 12.62 | 4,100 | 51,742 | 70,573,589 | Form |
| 5 | Patel, Snehal | CEO and CFO | Direct | Buy | 11282025 | 8.37 | 4,600 | 38,502 | 46,772,414 | Form |
| 6 | Patel, Snehal | CEO and CFO | Direct | Buy | 11122025 | 8.43 | 10,600 | 89,358 | 47,068,922 | Form |
| 7 | Patel, Snehal | CEO and CFO | Direct | Buy | 11042025 | 9.26 | 2,300 | 21,298 | 51,605,073 | Form |
| 8 | Patel, Snehal | CEO and CFO | Direct | Buy | 4292025 | 9.88 | 3,600 | 35,568 | 55,037,548 | Form |
| 9 | Patel, Snehal | CEO and CFO | Direct | Buy | 4222025 | 8.98 | 5,400 | 48,492 | 49,991,678 | Form |
| 10 | Patel, Snehal | CEO and CFO | Direct | Buy | 4082025 | 9.10 | 3,600 | 32,760 | 50,610,578 | Form |
| 11 | Patel, Snehal | CEO and CFO | Direct | Buy | 4072025 | 8.73 | 5,500 | 48,015 | 48,521,357 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/27/2026